Estrogens (Estrogen)

Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds.

Also Known As:

Networked: 40246 relevant articles (1553 outcomes, 5432 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Sasano, Hironobu: 113 articles (11/2015 - 01/2002)
2.	Hankinson, Susan E: 91 articles (12/2015 - 05/2002)
3.	Dowsett, Mitch: 85 articles (11/2015 - 01/2002)
4.	Suzuki, Takashi: 84 articles (10/2015 - 01/2002)
5.	Zheng, Wei: 76 articles (02/2016 - 03/2002)
6.	Jordan, V Craig: 76 articles (12/2015 - 01/2002)
7.	Chlebowski, Rowan T: 66 articles (09/2015 - 01/2002)
8.	Miki, Yasuhiro: 64 articles (11/2015 - 12/2002)
9.	Bernstein, Leslie: 59 articles (07/2015 - 01/2002)
10.	Hortobagyi, Gabriel N: 58 articles (12/2015 - 01/2002)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 03/01/2000 - "The current study was conducted to investigate the efficacy of GAP31 and MAP30 on estrogen-independent and highly metastatic human breast tumor MDA-MB-231 both in vitro and in vivo. " 05/01/1992 - "The results of this study with human breast cancer cells suggest that 5a may be highly effective in the treatment of estrogen-dependent breast cancer and/or in the prophylactic treatment of women with a high risk of breast cancer development." 01/01/2015 - "Because most of these Apiaceae spices are used widely with no known toxicity, the phytochemicals from the Apiaceae spices used in foods may be potentially protective against estrogen-mediated breast cancer." 08/23/2012 - "Endocrine therapies that inhibit estrogen receptor (ER)-α signaling are the most common and effective treatment for ER-α-positive breast cancer. " 06/15/2012 - "Although endocrine therapy has dramatically improved the treatment of breast cancer therapeutic resistance and tumour recurrence occurs, even in estrogen receptor (ER) positive cases. "
2.	Neoplasms (Cancer) 01/01/1988 - "The features that most influenced prognosis within the categories defined by site of first relapse were disease-free interval (less than 24 months v greater than or equal to 24 months), and estrogen receptor content in the primary tumor. " 10/01/1987 - "Because of its very high affinity and unusual dissociation kinetics, [3H]11 beta-CME2 should be a very useful ligand for studies of estrogen receptor dynamics and in the assay of estrogen receptor concentrations in tumors and tissues." 01/01/2004 - "In particular, we found a marked decrease in the number of apoptotic cells and debris after estrogen + irradiation, as compared to irradiation alone, only in younger patients and TNM 1+2 tumors. " 10/01/1994 - "One hundred sixty-seven good-risk patients with an estrogen receptor (ER+) positive recurrence or, in case of unknown receptor status, a disease-free interval (DFI) of greater than 12 months and < or = three recurrent tumor nodules each < or = 3 cm in diameter were entered onto the study. " 02/01/2016 - "Approximately 70% of breast cancers express the estrogen receptor, and endocrine-based therapies have significantly improved patient outcomes. "
3.	Osteoporosis 01/01/2015 - "Osteoporosis is one of the most frequent diseases in postmenopausal women, leading to an increased fracture risk due to the physiologic loss of the bone protective effects of estrogen. " 09/01/2009 - "Currently, the nonhuman primate is the most widely used large animal model to evaluate the safety and efficacy of new drug entities to treat or prevent estrogen-deficiency-induced bone loss and osteoporosis. " 01/01/2008 - "Because of the striking resemblance of skeletal responses in humans and rats in the state of estrogen deficiency, the ovx rat is considered to be a gold standard model for evaluating drugs for prevention and reversal of osteoporosis. " 07/01/2009 - "Although estrogens, are not any more the first choice therapy for osteoporosis, the are still important and promising treatment option for women after menopause. " 09/01/2001 - "Estrogen, especially when begun early in menopause, has been shown to be beneficial in the prevention and treatment of osteoporosis. "
4.	Cardiovascular Diseases (Cardiovascular Disease) 01/01/2014 - "Epidemiological studies have shown that estrogens have protective effects in cardiovascular diseases, even though the results from human clinical trials remain controversial, while most of the animal experiments confirmed this effect, but the detailed mechanism remains unclear. " 10/01/2003 - "At the cellular level, estrogens have many effects on cardiovascular cells capable of being interpreted as beneficial in terms of cardiovascular disease. " 01/01/2010 - "Cardiovascular disease (CVD) is more common in postmenopausal than premenopausal women, suggesting vascular protective effects of estrogen. " 11/01/2008 - "Cardiovascular disease (CVD) is more prevalent in postmenopausal than premenopausal women, suggesting vascular protective effects of estrogen. " 11/01/2001 - "It is widely accepted that in women, estrogens provide protection against the development of cardiovascular disease. "
5.	Carcinoma (Carcinomatosis) 09/02/2011 - "RPA extract includes chemical compounds with estrogen-like activity and validates its potential use as anticancer agent, particularly against breast carcinoma; provided important information potentially helpful in drug designing and discovery. " 02/15/1988 - "These characteristics are reflected in the marked efficacy with which it affects growth of estrogen-dependent 7,12-dimethylbenz(a)antracene-induced mammary carcinomas in intact female Sprague-Dawley rats. " 07/01/1975 - "In darkness the percentage of the take of the carcinoma proved to be less, and also the growth of the RMC-1 was delayed; there was also a marked increase in the efficacy of estrogen-therapy of mammary carcinoma. " 12/15/1980 - "This study corroborates previous reports which suggested the efficacy of estrogen receptor (ER) analysis in predicting responses of patients with metastatic mammary carcinoma to hormonal therapeutic manipulation. " 01/15/2011 - "Our findings highlight CXCR4 signaling as a rational therapeutic target for the treatment of ER-positive, estrogen-independent breast carcinomas needing improved clinical management."

Related Drugs and Biologics

1.	Tamoxifen
2.	Progesterone Receptors (Progesterone Receptor)
3.	Hormones
4.	Estrogens (Estrogen)
5.	Progesterone
6.	Aromatase Inhibitors
7.	Estrogen Receptor Modulators (Antiestrogen)
8.	Estradiol (Estrace)
9.	Progestins (Progestagens)
10.	Aromatase (CYP19)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
3.	Estrogen Replacement Therapy
4.	Ovariectomy (Oophorectomy)
5.	Castration